Skip to content
value.today

Pacific Diabetes Technologies, Inc.

🇺🇸 Portland, Oregon, USABiotechnologyFounded 2021
Total raised
$5 M
2 rounds on record
Latest round
$3 M
Oct 2025
First round on record
Mar 2025
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pacific Diabetes Technologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$3 MNo. 2$2 to $10 million

Pacific Diabetes Technologies, Inc.: Raise no. 2, Oct 2025

Investors in this round

15 investors had bought by the notice of Nov 17, 2025: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas Seidl · Executive Officer, Director, Promoter
  • Christopher Marsh · Director
  • Hank Wuh · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Erik Swanson, Power of Attorney for Thomas Seidl, President. Source: SEC Form D and 1 amendment, newest notice filed Nov 17, 2025. Read the notice at the SEC.

debt, optionsSEC
Mar 2025$2 MNo. 1$2 to $10 million

Pacific Diabetes Technologies, Inc.: Raise no. 1, Mar 2025

Investors in this round

5 investors had bought by the notice of Mar 14, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas Seidl · Executive Officer, Director
  • Christopher Marsh · Director
  • Ed La Cava · Director
  • Hank Wuh · Director
  • Kenneth Ward · Director
  • Mark Huber · Director
  • Peter Eckenberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Erik Swanson by POA for Thomas Seidl, President. Source: SEC Form D, newest notice filed Mar 14, 2025. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pacific Diabetes Technologies, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2025).

    SEC Form D · Nov 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2025

That is all the official record says: Pacific Diabetes Technologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Pacific Diabetes Technologies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pacific Diabetes Technologies, Inc.
NameRoleNamed in
Thomas SeidlExecutive officerNov 2025
Christopher MarshDirectorNov 2025
Hank WuhDirectorNov 2025
Thomas SeidlDirectorNov 2025
Ed La CavaDirectorMar 2025
Kenneth WardDirectorMar 2025
Mark HuberDirectorMar 2025
Peter EckenbergDirectorMar 2025
Thomas SeidlPromoterNov 2025